NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free XBIT Stock Alerts $7.95 -0.04 (-0.50%) (As of 01:11 PM ET) Add Compare Share Share Today's Range$7.84▼$8.2050-Day Range$4.20▼$7.9952-Week Range$3.05▼$8.20Volume18,870 shsAverage Volume48,229 shsMarket Capitalization$242.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get XBiotech alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About XBiotech Stock (NASDAQ:XBIT)XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Read More XBIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIT Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $5.74March 20, 2024 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insidersMarch 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! March 18, 2024 | investorplace.comXBIT Stock Earnings: XBiotech Reported Results for Q4 2023March 8, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechFebruary 17, 2024 | finance.yahoo.comXBIT Mar 2024 5.000 callJanuary 18, 2024 | morningstar.comXBiotech Inc XBITJanuary 8, 2024 | bizjournals.comA top Austin biopharmaceutical company is doubling down on its Austin campusMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…January 4, 2024 | finance.yahoo.comXBiotech to Begin Constructing New R&D Facility on its 48-acre CampusDecember 15, 2023 | msn.comARCT, EHTH and CRTO are among after hour moversDecember 5, 2023 | finance.yahoo.comCompanies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In GrowthNovember 14, 2023 | finanznachrichten.deXBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid ArthritisNovember 14, 2023 | finance.yahoo.comDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisSeptember 26, 2023 | finance.yahoo.comXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeAugust 8, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finance.yahoo.comXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialJune 30, 2023 | thestreet.comXBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyMay 23, 2023 | finanznachrichten.deXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finance.yahoo.comXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesApril 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finance.yahoo.comXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 9, 2023 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insidersFebruary 15, 2023 | finance.yahoo.comThe past three years for XBiotech (NASDAQ:XBIT) investors has not been profitableNovember 11, 2022 | finance.yahoo.comXBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)See More Headlines Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIT CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,560,000.00 Net MarginsN/A Pretax Margin-7,401.67% Return on Equity-10.82% Return on Assets-10.52% Debt Debt-to-Equity RatioN/A Current Ratio33.07 Quick Ratio33.07 Sales & Book Value Annual Sales$4.01 million Price / Sales59.91 Cash FlowN/A Price / Cash FlowN/A Book Value$7.19 per share Price / Book1.10Miscellaneous Outstanding Shares30,450,000Free Float21,803,000Market Cap$240.25 million OptionableOptionable Beta1.44 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. John Simard (Age 62)Founder, President, CEO & Chairman Comp: $4.67MDr. Sushma Shivaswamy Ph.D. (Age 46)Chief Scientific Officer Comp: $381.24kMs. Angela Hu (Age 40)Director of Finance, Principal Financial & Accounting Officer and Financial Controller Key CompetitorsFibroGenNASDAQ:FGENConduit PharmaceuticalsNASDAQ:CDTRigel PharmaceuticalsNASDAQ:RIGL23andMeNASDAQ:METrevi TherapeuticsNASDAQ:TRVIView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 9,068 shares on 3/11/2024Ownership: 2.896%Vanguard Group Inc.Bought 9,068 shares on 2/15/2024Ownership: 2.896%Bridgeway Capital Management LLCBought 5,352 shares on 2/15/2024Ownership: 0.475%Citadel Advisors LLCSold 5,200 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 26,279 shares on 2/13/2024Ownership: 0.260%View All Institutional Transactions XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed in 2024? XBiotech's stock was trading at $4.00 on January 1st, 2024. Since then, XBIT shares have increased by 97.3% and is now trading at $7.89. View the best growth stocks for 2024 here. When is XBiotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our XBIT earnings forecast. What is John Simard's approval rating as XBiotech's CEO? 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ). When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. Who are XBiotech's major shareholders? XBiotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.90%), Vanguard Group Inc. (2.90%), Bridgeway Capital Management LLC (0.48%), Northern Trust Corp (0.26%), National Bank of Canada FI (0.08%) and Citadel Advisors LLC (0.00%). View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.